Humidifeye, AesculaTech’s groundbreaking treatment for Dry Eye, treated 22 patients in a 3-month OUS first in Human study. Study endpoints included safety, signs, symptoms, and patient-reported metrics for satisfaction. Data will be made public over the coming months, but a quick summary is provided below:
- Rapid and sustained improvements in signs, including reduction in corneal epitheliopathy
- Progression from severe to normal condition based on Ocular Surface Disease Index (OSDI) scoring
- Improvement in quality of life noted by ALL participants
These outcomes provide concrete and statistically significant data that the Humidifeye device can improve dry eye outcomes and will serve as the launching point for efforts in the US. We encourage press and anyone interested in collaboration or investment to reach out. https://aesculatech.com/contact/